Mode of Action of MetrioPharm’s Lead Molecule MP1032: Video Presentation by Dr. Brysch・MetrioPharm AG Company Calendar 2024・MetrioPharm AG informs
Video Presentation by Dr. Brysch
MetrioPharm AG is developing MP1032, a completely novel molecule that is not only extremely safe but can also be used to treat a variety of different diseases. A clinical study in COVID-19 has been successfully completed, and another in the orphan indication Duchenne muscular dystrophy is underway.
How can the molecule have such a wide range of efficacy and at the same time cause so few side effects? MetrioPharm has prepared a video presentation with CSO Dr. Wolfgang Brysch that explains how MP1032 works in just four minutes. He explains how MP1032 acts inside macrophages and other cells to regulate the mitochondria, the so-called “power plants of the cell”, and to normalize various disease processes at an early stage. Here you can watch this video before it is published on our other channels.
If you would like to learn more about the scientific background of MetrioPharm’s work and the enormous significance of disrupted mitochondrial signals for the development of inflammatory processes and chronic diseases, you can find open access publications on this topic here and here:
- On the role of disturbed macrophage metabolism in the development of disease processes
- On the link between mitochondria and proper immune function
MetrioPharm AG Company Calendar 2024
- 06.-07. January, Longwood Healthcare Leaders Conference at JPMorgan Healthcare Conference, San Francisco, USA
- 09. January, Annual Wuxi Global Forum 2024, San Francisco, USA
- 08.-10. January, Biotech Showcase at JPMorgan Healthcare Conference, San Francisco, USA
- 10. January, FreeMind’s Annual Non-Dilutive Funding Summit, San Francisco, USA
- 26.-27. February, BIO CEO & Investor Conference, New York, USA
- 29. February, Sachs Annual European Life Sciences CEO Forum, Zurich, Switzerland
- 01.-02. March, Duchenne UK 2024 New Horizons Conference, London, UK
- 03.-06. March, Muscular Dystrophy Association (MDA) Conference, Orlando, USA
- 18.-20. March, Bio-Europe Spring, Barcelona, Spaain
- 22.-23. April, Swiss Biotech Day, Basel, Switzerland
- 24.-25. April, Asia Bio Partnering Forum, Singapur
- 29.-30. April, LSX World Congress, Biotech, Healthtech, Medtech, London, UK
- 12.-14. Mai, BioEquity Europe, San Sebastian, Spain
- 03.-06. June, BIO International Convention, San Diego, USA
- 27.-30. June, Parents Project Muscular Dystrophy (PPMD) 30th Annual Conference, Orlando, USA
- 09. July, Biotech Finanz-Gipfel 2024, Berlin, Germany
- 10.-11. September, ChinaBio Partnering Forum 2024, Shanghai, China
- 17.-18. September, HealthTech Innovation Days, Paris, France
- 25.-26. September, 24. Annual Biotech in Europe Forum, Basel, Switzerland
- 08.-12. October, World Muscle Society Annual Congress, Prag, Czech Republic
- 29.-31. October, 15. World Congress on Targeting Mitochondria, Berlin, Germany
- 04.-06. November, BIO-Europe Conference, Stockholm, Sweden
- 18. November, LSX Investival Showcase Conference, London, UK
- 19.-21. November, Jefferies 2024 London Healthcare Conference, London, UK
MetrioPharm AG informs
MetrioPharm uses various channels to inform its shareholders:
In addition to the quarterly newsletter, we also keep you informed about current events in the company with press releases. The press releases can also be found on our website here. If you have not yet been added to our distribution list for press releases, please send us an e-mail at and we will add you to the distribution list as soon as possible.
You can also network with MetrioPharm via LinkedIn. We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments. Please feel free to include us in your LinkedIn community by invitation.
Contact:
MetrioPharm
Investor Relations
T + 41 44 552 7190
E
W www.metriopharm.com